Biovail Ralivia ER “Approvable” At FDA Pending Further Clinical Information
This article was originally published in The Pink Sheet Daily
Executive Summary
The company believes that the Ralivia ER NDA has sufficient data to fulfill FDA’s request. Biovail is seeking a U.S. marketing partner for the long-acting opioid analgesic.